Senores Pharma Q4 & FY26 Revenue Surges 66% to ₹190 Cr; PAT Jumps 104% to ₹37 Cr
Senores Pharmaceuticals reported Audited Consolidated Financial Results for Q4 & FY26 ended March 31, 2026. Q4 FY26 saw Total Income rise 66% to ₹190 Cr, EBITDA up 219% to ₹62 Cr, and PAT grow 104% to ₹37 Cr. FY26 Total Income increased 65% to ₹664 Cr, EBITDA rose 114% to ₹200 Cr, and PAT grew 108% to ₹122 Cr. The company also highlighted strategic acquisitions and joint ventures.
The announcement details substantial financial growth, strategic acquisitions, and market expansion, which are likely to have a significant positive impact on investor sentiment and the company's future performance.
The company reported significant year-on-year growth in total income, EBITDA, and PAT for both the quarter and the full financial year. Strategic acquisitions and joint ventures were also highlighted, indicating positive future growth prospects.
Senores Pharmaceuticals Limited announced its Audited Financial Results for the 4th Quarter and Full year ended 31st March 2026, reporting a strong financial and operational performance.
For the 4th Quarter of FY26, the company reported a Total Income of ₹190 Crores, a significant increase of 66% compared to the same period last year. EBITDA stood at ₹62 Crores, up by 219%, and Profit After Tax (PAT) grew by 104% to ₹37 Crores.
For the Full Financial Year 2026, Total Income increased by 65% to ₹664 Crores. EBITDA surged by 114% to ₹200 Crores, and PAT saw a substantial rise of 108% to ₹122 Crores.
The company highlighted strong segment revenue growth, with Regulated Markets revenue growing by 169% year-on-year in Q4 FY26 and 90.6% for the full year FY26. Emerging Markets showed steady growth of 5.7% in Q4 FY26 and 13.1% for FY26. The Branded Generics business demonstrated remarkable growth, with revenue increasing by 132.4% in Q4 FY26 and a staggering 385.3% for FY26.
Key business highlights include the acquisition of a 51% membership interest in Zoraya Pharmaceuticals, LLC, USA, to strengthen vertical integration and serve as a dedicated market-facing brand. Phase 1 of the acquisition of Apnar Pharmaceuticals, completing a 75% stake, has been finalized, with Phase 2 expected by Q2FY27. Additionally, the company entered into a 70% joint venture, Amerisyn, in the U.S. to supply pharmaceuticals to federal, veterans, and defense sectors.
Managing Director Swapnil Shah commented on the robust performance, attributing it to operational discipline and strong momentum in key growth areas. He noted the expansion of the approved ANDA portfolio to 51 from 26 in the previous year, with 30 approved ANDAs yet to be commercialized. The acquisition of Apnar Pharmaceuticals is expected to enhance scalability and accelerate product launches, with initial revenues recorded in Q4FY26 and significant scaling anticipated within 12-18 months. The joint venture Amerisyn marks a key milestone for U.S. operations, providing direct access to the U.S. government procurement market. The Emerging Markets business is on a steady trajectory with mid-teen EBITDA margins and is now cash flow positive.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.